{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-157096","form_type":"8-K","ticker":"PSNL","cik":"0001527753","company_name":"Personalis, Inc.","filed_at":"2025-07-09T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.233499+00:00","generated_at":"2026-05-18T08:52:21.772832+00:00","sec_items":["1.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Personalis expands Tempus partnership to colorectal cancer MRD; term to 2029","bullets":["Tempus authorized to market NeXT Personal MRD test for colorectal cancer, fourth indication.","Agreement term extended to November 25, 2029.","Exclusivity period extended to December 31, 2028 for both parties on tumor-informed MRD in these indications.","Standstill restrictions for Tempus modified to expire June 4, 2027 or end of exclusivity."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-157096","json":"https://secwatch.observer/filing/0001193125-25-157096.json","markdown":"https://secwatch.observer/filing/0001193125-25-157096.md","text":"https://secwatch.observer/filing/0001193125-25-157096.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1527753/000119312525157096/0001193125-25-157096-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1527753/000119312525157096/d26859d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T08:52:21.772832+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}